Sierra LeoneTuberculosis profile
Population  2014 6.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.8 (1.9–3.9) 45 (30–62)
Mortality (HIV+TB only) 0.7 (0.47–0.98) 11 (7.4–16)
Prevalence  (includes HIV+TB) 28 (14–46) 441 (228–722)
Incidence  (includes HIV+TB) 20 (15–25) 310 (235–394)
Incidence (HIV+TB only) 2.3 (1.7–3) 37 (28–47)
         
Case detection, all forms (%) 64 (50–84)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
200 (35–360) 89 (23–160)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 453   276
Pulmonary, clinically diagnosed 4 239   0
Extrapulmonary 509    
       
Total new and relapse 12 477    
Previously treated, excluding relapses 244    
Total cases notified 12 721    
Among 7 453 new and relapse cases:
135 (2%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 11 048 (87)
HIV-positive TB patients 1 305 (12)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 816 (63)
HIV-positive TB patients on antiretroviral therapy (ART) 887 (68)
HIV-positive people screened for TB 10 473  
HIV-positive people provided with IPT 1 339  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (87) 7 795
Previously treated cases registered in 2013 (71) 324
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 7.3
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-25 Data: www.who.int/tb/data